Latest Ciprofloxacin Stories
MALVERN, Pa., Dec.
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2008. Revenue for the third quarter was $197,000, compared with revenue of $230,000 for the third quarter of 2007.
Novexel, a specialty pharmaceutical company, has initiated Phase II clinical trial of its advanced injectable antibacterial, which combines the company's broad spectrum beta-lactamase inhibitor, NXL104, with cephalosporin antibiotic, ceftazidime.
SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL(R) (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).
WASHINGTON, Oct. 27 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida.
Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m.
Aradigm has completed enrollment in its Phase II clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. The study was initiated in July 2008 in bronchiectasis centers in the UK and enrolled a total of 36 patients as planned.
Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.
Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.